FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Trump Maintains Iran Blockade, Rejects Proposal; US Prepares Potential Strike Plan

By

-- US President Donald Trump said he will maintain a US naval blockade on Iran, rejecting Tehran's proposal while pushing for a stricter nuclear agreement, Axios reported Wednesday.

Trump dismissed Iran's request to reopen the Strait of Hormuz before nuclear talks, choosing instead to sustain pressure until Tehran agrees to US demands.

US Central Command has drafted plans for a short but intense strike campaign targeting Iranian infrastructure to break the current negotiating impasse, three sources familiar with the matter told Axios.

Officials expect any military action to hit key infrastructure, after which Washington would push Iran back into negotiations with greater concessions, the sources said.

Trump said he prefers the blockade over immediate military action, calling it more effective leverage, and he has not authorized strikes as of Tuesday night, according to the sources.

The US President views the blockade as his primary tool but remains open to military action if Iran refuses to compromise on nuclear demands, the report added, citing sources.

"The blockade is somewhat more effective than the bombing," Trump told Axios.

He added that Iran wanted to settle, "They don't want me to keep the blockade. I don't want to [lift the blockade], because I don't want them to have a nuclear weapon."

The president said Iran faces severe economic strain under the blockade and suggested Tehran seeks a deal to ease restrictions and resume exports, according to the report.

He added that Iran's oil storage and pipeline systems are approaching critical limits and are "getting close to exploding" as exports stall. However, some analysts question the immediacy of that risk, the report said.

An Iranian security official warned that the blockade will trigger an unprecedented response if it continues, signaling rising tensions, according to state-affiliated Press TV, cited by the report.

The source said Iranian forces have shown restraint to allow diplomacy but stressed patience will not last if pressure tactics persist, the report added.

Iran's military leadership believes a strong retaliatory move may become necessary if negotiations fail and the blockade remains in place, according to the report.

On Wednesday, Trump posted on Truth Social, "Iran can't get their act together. They don't know how to sign a nonnuclear deal. They better get smart soon!"

has reached out to the White House and US Central Command for any comments.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Research

Research Alert: CFRA Downgrades Rating To Sell From Hold On Shares Of Essex Property Trust, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target by $15 to $250 using a narrower equity risk premium and a forward P/FFO of 15.5x, which is in line with the multifamily residential REIT average. We keep our 2026 FFO estimate at $16.15 and lower 2027's by $0.05 to $16.45 on respective revenue projections of $1.94B and $1.98B. Rental revenue is not yet rebounding to historical growth levels. Across the industry, we are seeing inflation in key operating expenses exceeding revenue growth, and this leads to modest gains in cash NOI growth Y/Y. We expect these market conditions to continue as pricing power for ESS and its peers seems to have eased. In particular, ESS has a West Coast portfolio profile that is exposed to significant job layoffs in the technology sector. In our opinion, we have not yet seen the tail risk of major announcements just released in recent weeks. ESS has the challenge of complying with strict housing guidelines in California, leading to the trust historically underperforming peers in other parts of the country.

$ESS
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Biogen Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $236, 13.8x our new 2027 EPS view, a discount to BIIB's five-year historical forward P/E average of 14.1x. We lower our 2026 EPS view to $15.24 from $16.14 to adjust for the impact from acquired IPR&D. We keep our 2027 EPS view at $17.16. BIIB reported a strong start to 2026, with sales of $2.5B and adjusted EPS of $3.57. We see a successful stabilization of the business after years of decline, due to a 12% Y/Y increase in the growth products portfolio. In our view, during the analyst call, management presented a clear strategic vision centered on the pending $5.6B acquisition of Apellis, expected to close in Q2, which can transform BIIB into a growth company by adding two commercial assets, Syfovre and Empaveli. We think the Apellis deal could bridge a revenue gap until 2028, when the company's late-stage pipeline matures. Via this acquisition, BIIB also gains nephrology expertise and an established infrastructure, which could set its key asset Felzartamab launch for success.

$BIIB
Australia

Starbucks to Sustain Sales Momentum; to Focus on Margins in H2, UBS Says

Starbucks (SBUX) is expected to maintain solid sales momentum on its turnaround strategy, though investor focus is shifting toward margin recovery in H2, UBS said in a note on Wednesday.The brokerage said strong transaction-driven comparable sales growth in Q2 reflected improvements in operations, menu innovation and updated loyalty program.Looking ahead, UBS said continued execution on initiatives such as afternoon beverage platforms, loyalty enhancements, store closures and operational improvements should support sales into H2.UBS also expects margin expansion later in the year, supported by sales leverage, cost savings and easing pressures from tariffs and coffee costs.UBS raised the price target on the stock to $105 from $100 but maintained a neutral rating.Price: $106.10, Change: $+8.82, Percent Change: +9.06%

$SBUX